PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) and Sartorius (OTCMKTS:SARTF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Volatility & Risk
PROCEPT BioRobotics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Sartorius has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Earnings and Valuation
This table compares PROCEPT BioRobotics and Sartorius”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PROCEPT BioRobotics | $308.05 million | 4.87 | -$95.57 million | ($1.82) | -14.47 |
| Sartorius | $3.66 billion | 2.12 | $90.90 million | $2.15 | 105.58 |
Sartorius has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Sartorius, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for PROCEPT BioRobotics and Sartorius, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PROCEPT BioRobotics | 2 | 4 | 8 | 0 | 2.43 |
| Sartorius | 0 | 0 | 0 | 1 | 4.00 |
PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 57.44%. Given PROCEPT BioRobotics’ higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Sartorius.
Institutional and Insider Ownership
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares PROCEPT BioRobotics and Sartorius’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PROCEPT BioRobotics | -31.82% | -27.70% | -20.29% |
| Sartorius | 3.82% | 8.19% | 3.15% |
Summary
Sartorius beats PROCEPT BioRobotics on 10 of the 15 factors compared between the two stocks.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
About Sartorius
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
